[en] Besides genetic predisposition, obesity is the most important risk factor for the development of diabetes mellitus, and weight reduction has been shown to markedly improve blood glucose control in obese subjects with type 2 diabetes. Therapeutic strategies for the obese diabetic patient include: 1) promoting weight loss through lifestyle modifications (hypocaloric diet and exercise) and anti-obesity drugs (orlistat, sibutramine, etc.); 2) improving blood glucose control, essentially through the reduction of insulin resistance (metformin, eventually thiazolidinediones) or insulin need (alpha-glucosidase inhibitors) and, at a later stage, the correction of defective insulin secretion (sulphonylureas, repaglinide) or low circulating insulin levels (exogenous insulin); and 3) treating common associated risk factors, such as arterial hypertension and dyslipidaemias, to improve cardiovascular prognosis. When morbid obesity is present, both restoring a good glycemic control and correcting associated risk factors can only be obtained through marked and sustained weight loss. This primary objective justifies more aggressive weight reduction programmes, including very low-calorie diets and bariatric surgery, but only within a multidisciplinary approach and in well-selected patients.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Language :
English
Title :
Treatment of diabetes in patients with severe obesity.
American Diabetes Association. Consensus statement. The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1995; 18: 1510-8.
Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15: 755-72.
Bosello O, Armellini F, Zamboni M, Fitchet M. The benefits of modest weight loss in type II diabetes. Int J Obesity 1997; 21 Suppl 1: S10-3.
Bray GA, Ryan DH. Drugs used in the treatment of obesity. Diabetes Rev 1997; 5: 83-103.
Brown SA, Upchurch S, Anding R, Winter M, Ramirez G. Promoting weight loss in type II diabetes. Diabetes Care 1996; 19: 613-24.
Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. A randomized controlled trial. JAMA 1999; 281: 235-42.
Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med 1997; 102: 99-110.
DeFronzo RA, Ferrannini E. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-94.
Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995; 49: 721-49.
Franz MJ. Lifestyle modifications for diabetes management. Endocrinol Metab Clin North Am 1997; 26: 499-510.
Garg A, Grundy SM. Diabetic dyslipidemia and its therapy. Diabetes Rev 1997; 5: 425-33.
Gumbiner B. Treating obesity in type 2 diabetes. Calories, composition, and control. Diabetes Care 1999; 22: 886-8.
Heath MJ, Chong E, Weinstein SP, Seaton TB. Sibutramine enhances weight loss and improves glycemie control and plasma lipid profile in obese patients with type 2 diabetes [abstract]. Diabetes 1999; 48 Suppl 1: A308.
Henry RR. Thiazolidinediones. Endocrinol Metab Clin North Am 1997; 26: 553-73.
Henry RR, Gumbiner B. Benefits and limitations of very-low-calorie diet therapy in obese NIDDM. Diabetes Care 1991; 14: 802-23.
Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998; 21: 1288-94.
Holman RR, Cull CA, Turner RC on behalf of the UKPDS Study Group. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemie control over 3 years. U.K. Prospective Diabetes Study 44. Diabetes Care 1999; 22: 960-4.
Kelley DE. Effects of weight loss on glucose homeostasis in NIDDM. Diabetes Rev 1995; 3: 366-77.
Lebovitz HE. Stepwise and combination drug therapy for the treatment of NIDDM. Diabetes Care 1994; 17: 1542-4.
Lebovitz HE. a-glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev 1998; 6: 132-45.
MacDonald KG, Long SD, Swanson MS, Brown BM, Morris P, Dohm GL, et al. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J Gastrointest Surg 1997; 1: 213-20.
Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity. Application to type 2 diabetes. Diabetes Care 1997; 20: 1744-66.
Makrikalis K, Bakris G. Diabetic hypertensive patients: Improving their prognosis. J Cardiovasc Pharmacol 1998; 31 Suppl 2: S34-S40.
McNeely W, Benfield P. Orlistat. Drugs 1998; 56: 241-9.
McNeely W, Goa KL. Sibutramine. A review of its contribution to the management of obesity. Drugs 1998 ; 56: 1093-124.
Pi-Sunyer FX. A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity. Clin Ther 1996; 18: 1006-35.
Pories WJ, MacDonald KG, Flickinger EG, Dohm GL, Sinha MK, Barakat HA, et al. Is type II diabetes mellitus (NIDDM) a surgical disease? Ann Surg 1992; 215: 633-43.
Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 1995; 222: 339-52.
Pyörälä K, Pedersen TE, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G, and the Scandinavian Simvastatin Survival Study (4S) Group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997; 20: 614-20.
Redmon JB, Raatz SK, Kwong CA, Swanson JE, Thomas W, Bantle JP. Pharmacological induction of weight loss to treat type 2 diabetes. Diabetes Care 1999; 22: 896-903.
Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996; 45: 1661-9.
Scheen AJ. Insulin therapy in the treatment of NIDDM. IDF Bulletin 1996; 41: 16-8.
Scheen AJ. Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s: Achievements and future developments. Drugs 1997; 54: 355-68.
Scheen AJ. Aggressive weight reduction treatment in the management of type 2 diabetes. Diab Metab 1998; 23: 116-23.
Scheen AJ. Clinical efficacy of acarbose in the treatment ot diabetes: A critical review of controlled trials. Diab Metab 1998; 24: 311-20.
Scheen AJ, Lefèbvre PJ. Pharmacological treatment of the obese diabetic patient. Diab Metab 1993; 19: 547-59.
Scheen AJ, Lefèbvre PJ. Pathophysiology of type 2 diabetes. In: Kuhlmann J, Puls W, eds. Handbook of Experimental Pharmacology, Oral Antidiabetics. Berlin: Springer Verlag; 1996. p. 7-42.
Scheen AJ, Lefèbvre PJ. Oral antidiabetic agents: A guide to selection. Drugs 1998; 55: 225-36.
Scheen AJ, Lefèbvre PJ. Pharmacological treatment of obesity: Present status. Int J Obes 1999; 23 Suppl 1: 47-53.
Scheen AJ, Lefèbvre PJ. Management of the obese diabetic patient. Diabetes Rev 1999; 7: 77-93.
Scheen AJ, Lefèbvre PJ. Troglitazone. Antihyperglycemic activity and potential role in the treatment of type 2 diabetes. Diabetes Care 1999; 22: 1568-77.
Scopinaro N, Adami GF, Marinari GM, Gianetta E, Traverse E, Friedman D, et al. Biliopancreatic diversion. World J Surg 1998; 22: 936-46.
Shepherd G. Fitchet M, Kelly F. Sibutramine: A meta-analysis of the change in fasting plasma glucose in patients with a high baseline fasting value (≥ 5.5 mmol/l) [abstract]. Int J Obesity 1997; 21 Suppl 2: S54.
Sjöström I., Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HPF, et al. for the European Multicentre Orlistat Study Group. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167-73.
Spencer CM, Markham A. Troglitazone. Drugs 1997; 54: 89-101.
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. Br Med J 1998; 317: 703-13.
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.